CapsoVision Inc (CV)

Currency in USD
6.110
-0.200(-3.17%)
Closed·
6.1100.000(0.00%)
·

CV Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
-0.15 / -0.11
Revenue / Forecast
3.57M / --
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09-0.150/-0.1103.57M/---36.36%--Free Sign Up
2026/06-0.150/-0.1103.60M/---36.36%--Free Sign Up
2026/03-0.150/-0.1102.80M/---36.36%--Free Sign Up
2025/12-0.160/-0.1003.90M/---60%--Free Sign Up
2025/09-0.170/--3.54M/------Free Sign Up
2025/06-2.02/--3.32M/------Free Sign Up
2025/03-2.49/--2.79M/------Free Sign Up

All numbers in USD

CapsoVision Inc Earnings Call Summary for Q3/2026

  • Q3 revenue rose 1% to $3.6M; net loss narrowed to $7.3M ($0.15/share) from $7.9M ($0.17/share) year-over-year as operating expenses fell 8.1%.
  • FDA-cleared AI Highlights tool launched Nov. 2 for CapsoCam Plus; management expects full commercial impact to materialize in 2027, not current quarter.
  • Gross margin compressed to 49% from 54% due to higher material costs, inventory obsolescence, and stock-based compensation expenses.
  • Company raised $19.5M in capital, ending quarter with $21.8M cash; plans FDA submission for CapsoCam Colon by year-end 2026 after study completion.
  • Analysts set price targets of $9-$10 (50% upside); management forecasts stronger H2 2026 as large customers awaited FDA clearance before purchasing.
Last Updated: 2026-11-12, 05:14 p/m
Read Full Transcript

FAQ

What Is CapsoVision's Earnings Per Share (TTM)?

The CapsoVision EPS (TTM) is -0.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.